PE20020210A1 - Indoloquinazolinonas como inhibidores de poli(adp-ribosa)polimerasa (parp) - Google Patents
Indoloquinazolinonas como inhibidores de poli(adp-ribosa)polimerasa (parp)Info
- Publication number
- PE20020210A1 PE20020210A1 PE2001000700A PE2001000700A PE20020210A1 PE 20020210 A1 PE20020210 A1 PE 20020210A1 PE 2001000700 A PE2001000700 A PE 2001000700A PE 2001000700 A PE2001000700 A PE 2001000700A PE 20020210 A1 PE20020210 A1 PE 20020210A1
- Authority
- PE
- Peru
- Prior art keywords
- indoloquinazolinones
- alkyl
- polymerase
- refers
- poly
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical class [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 abstract 1
- SRNWOUGRCWSEMX-ZQSHOCFMSA-N ADP-alpha-D-ribose Chemical compound O([P@](O)(=O)O[P@](O)(=O)OC[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)C[C@H]1O[C@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-ZQSHOCFMSA-N 0.000 abstract 1
- -1 CARBOXYL Chemical class 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 230000005779 cell damage Effects 0.000 abstract 1
- 208000037887 cell injury Diseases 0.000 abstract 1
- 230000017074 necrotic cell death Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0017508.3A GB0017508D0 (en) | 2000-07-17 | 2000-07-17 | Antimicrobials |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20020210A1 true PE20020210A1 (es) | 2002-04-04 |
Family
ID=9895801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2001000700A PE20020210A1 (es) | 2000-07-17 | 2001-07-12 | Indoloquinazolinonas como inhibidores de poli(adp-ribosa)polimerasa (parp) |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6964960B2 (https=) |
| EP (1) | EP1303517B1 (https=) |
| JP (1) | JP3939246B2 (https=) |
| CN (1) | CN1183136C (https=) |
| AR (1) | AR031379A1 (https=) |
| AT (1) | ATE262530T1 (https=) |
| AU (1) | AU2001279754A1 (https=) |
| BR (1) | BR0112521A (https=) |
| CA (1) | CA2415683C (https=) |
| DE (1) | DE60102473T2 (https=) |
| DK (1) | DK1303517T3 (https=) |
| ES (1) | ES2218439T3 (https=) |
| GB (1) | GB0017508D0 (https=) |
| MY (1) | MY133969A (https=) |
| PE (1) | PE20020210A1 (https=) |
| PT (1) | PT1303517E (https=) |
| TR (1) | TR200401026T4 (https=) |
| WO (1) | WO2002006284A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6956035B2 (en) | 2001-08-31 | 2005-10-18 | Inotek Pharmaceuticals Corporation | Isoquinoline derivatives and methods of use thereof |
| JP2007501857A (ja) | 2003-02-28 | 2007-02-01 | イノテック ファーマシューティカルズ コーポレーション | 四環系ベンズアミド誘導体およびその使用方法 |
| RU2007135362A (ru) | 2005-02-25 | 2009-03-27 | Инотек Фармасьютикалз Корпорейшн (Us) | Тетрациклические амино- и карбоксамидосоединения и способ их применения |
| CN101316592A (zh) | 2005-08-24 | 2008-12-03 | 伊诺泰克制药公司 | 茚并异喹啉酮类似物及其用法 |
| ES2559679T3 (es) | 2006-06-20 | 2016-02-15 | Abbvie Inc. | Pirazoloquinazolinonas como inhibidores de PARP |
| GB0615809D0 (en) * | 2006-08-09 | 2006-09-20 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| GB0701273D0 (en) * | 2007-01-24 | 2007-02-28 | Angeletti P Ist Richerche Bio | New compounds |
| MX2009009183A (es) | 2007-02-28 | 2009-09-07 | Inotek Pharmaceuticals Corp | Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos. |
| EP2409700A1 (en) | 2007-05-08 | 2012-01-25 | Schering Corporation | Methods of treatment using intravenous formulations comprising temozolomide |
| RU2606635C2 (ru) * | 2011-07-13 | 2017-01-10 | Сантен Фармасьютикал Ко., Лтд. | Новое соединение, проявляющее ингибиторную активность в отношении parp |
| CN102766144B (zh) * | 2012-07-10 | 2014-04-23 | 浙江大学 | 一种吲哚并[1,2-c]喹唑啉化合物的制备方法 |
| JP6457696B2 (ja) | 2015-07-23 | 2019-01-23 | アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ | 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用 |
| GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
| WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
| KR20200130856A (ko) | 2018-03-13 | 2020-11-20 | 옹쎄오 | 암 치료에서 획득한 내성에 대한 디베이트 분자 |
| KR20210097733A (ko) * | 2018-11-30 | 2021-08-09 | 메르크 파텐트 게엠베하 | 전자 디바이스용 화합물 |
| EP3938367A1 (de) * | 2019-03-12 | 2022-01-19 | Merck Patent GmbH | Materialien für organische elektrolumineszenzvorrichtungen |
| CN110357892B (zh) * | 2019-07-10 | 2022-06-07 | 云南大学 | 四氢嘧啶并[1,2-a]吲哚衍生物及其合成方法与应用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN114195789B (zh) * | 2021-12-15 | 2022-09-09 | 广东海洋大学 | 一种无金属参与的多环吲哚衍生物的制备方法 |
| KR20260030809A (ko) | 2023-06-21 | 2026-03-06 | 테트라곤 바이오사이언시스 엘티디 | Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3635966A (en) | 1969-10-22 | 1972-01-18 | Robins Co Inc A H | 6-substituted-indolo(1 2-c)quinazolines |
| DE2237372C3 (de) | 1972-07-29 | 1981-07-09 | Basf Ag, 6700 Ludwigshafen | Heterocyclische Farbstoffe, ihre Herstellung und ihre Verwendung |
| US5441955A (en) * | 1993-11-19 | 1995-08-15 | Pathogenesis Corporation | Indolo[2,1-biquinazoline-6,12-dione antibacterial compounds and methods of use thereof |
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
-
2000
- 2000-07-17 GB GBGB0017508.3A patent/GB0017508D0/en not_active Ceased
-
2001
- 2001-07-12 PE PE2001000700A patent/PE20020210A1/es not_active Application Discontinuation
- 2001-07-13 AR ARP010103339A patent/AR031379A1/es not_active Application Discontinuation
- 2001-07-13 MY MYPI20013343 patent/MY133969A/en unknown
- 2001-07-16 CA CA002415683A patent/CA2415683C/en not_active Expired - Fee Related
- 2001-07-16 ES ES01957972T patent/ES2218439T3/es not_active Expired - Lifetime
- 2001-07-16 US US10/333,186 patent/US6964960B2/en not_active Expired - Fee Related
- 2001-07-16 TR TR2004/01026T patent/TR200401026T4/xx unknown
- 2001-07-16 EP EP01957972A patent/EP1303517B1/en not_active Expired - Lifetime
- 2001-07-16 WO PCT/EP2001/008192 patent/WO2002006284A1/en not_active Ceased
- 2001-07-16 AU AU2001279754A patent/AU2001279754A1/en not_active Abandoned
- 2001-07-16 AT AT01957972T patent/ATE262530T1/de not_active IP Right Cessation
- 2001-07-16 DK DK01957972T patent/DK1303517T3/da active
- 2001-07-16 PT PT01957972T patent/PT1303517E/pt unknown
- 2001-07-16 BR BR0112521-4A patent/BR0112521A/pt not_active Application Discontinuation
- 2001-07-16 DE DE60102473T patent/DE60102473T2/de not_active Expired - Lifetime
- 2001-07-16 JP JP2002512186A patent/JP3939246B2/ja not_active Expired - Fee Related
- 2001-07-16 CN CNB018126995A patent/CN1183136C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| DE60102473D1 (de) | 2004-04-29 |
| GB0017508D0 (en) | 2000-08-30 |
| HK1056872A1 (en) | 2004-03-05 |
| AU2001279754A1 (en) | 2002-01-30 |
| CN1183136C (zh) | 2005-01-05 |
| CN1441803A (zh) | 2003-09-10 |
| JP2004504323A (ja) | 2004-02-12 |
| US20030199502A1 (en) | 2003-10-23 |
| DE60102473T2 (de) | 2005-02-03 |
| CA2415683A1 (en) | 2002-01-24 |
| AR031379A1 (es) | 2003-09-24 |
| JP3939246B2 (ja) | 2007-07-04 |
| TR200401026T4 (tr) | 2004-07-21 |
| WO2002006284A1 (en) | 2002-01-24 |
| ES2218439T3 (es) | 2004-11-16 |
| HK1055426A1 (en) | 2004-01-09 |
| ATE262530T1 (de) | 2004-04-15 |
| BR0112521A (pt) | 2003-07-01 |
| PT1303517E (pt) | 2004-07-30 |
| MY133969A (en) | 2007-11-30 |
| EP1303517B1 (en) | 2004-03-24 |
| CA2415683C (en) | 2009-12-29 |
| US6964960B2 (en) | 2005-11-15 |
| DK1303517T3 (da) | 2004-06-21 |
| EP1303517A1 (en) | 2003-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20020210A1 (es) | Indoloquinazolinonas como inhibidores de poli(adp-ribosa)polimerasa (parp) | |
| PE20020051A1 (es) | Metodos y composiciones que comprenden nucleosidos para tratar flavivirus y pestivirus | |
| BR0309475A (pt) | Derivados de pirazolo-[1,5-a]-pirimidina e inibidores de nad(p)h oxidase que contêm os mesmos | |
| AR109354A2 (es) | Una composición que comprende un compuesto bicíclico y compuesto | |
| SV2002000195A (es) | Compuestos farmaceuticamente activos ref. pcs10342 afae/bb | |
| EP1320522B8 (en) | Compositions and methods of the use thereof achiral analogues of cc-1065 and the duocarmycins | |
| EA200100412A1 (ru) | Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ | |
| AR017700A1 (es) | Un compuesto derivado de imidazol, un procedimiento para prepararlo, compuestos utiles como intermediarios para prepararlo, y una composicionfarmaceutica que comprende a dicho compuesto derivado de imidazol | |
| DK0931788T3 (da) | Metalloproteasehæmmere | |
| TR200103493T2 (tr) | Metaloproteaz önleyicileri | |
| CO5251404A1 (es) | Compuestos antibioticos de azalida | |
| GT200100117A (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| PE20020874A1 (es) | Pirimidinas inhibidoras de metaloproteinasas de matriz | |
| TWI348371B (https=) | ||
| PE71599A1 (es) | Inhibidores de proteasas | |
| DK1001930T3 (da) | N-hydroxyformamidderivater som inhibitorer af matrix-metalloproteinaser | |
| DK1204650T3 (da) | Substituerede 2-arylbenzazol-forbindelser og anvendelse deraf som antitumormidler | |
| NO307463B1 (no) | Galantaminderivater, en fremgangsmõte for fremstilling samt deres anvendelse som medikamenter | |
| AU2003250471A8 (en) | Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors | |
| DK1066291T3 (da) | Svampedræbende 6-(2-halogen-4-alkoxyphenyl)-triazolopyrimidiner | |
| PE20050312A1 (es) | Compuestos de peptidilo como inhibidores de catepsina s | |
| DE69917000D1 (de) | Butorphanol enthaltende formulierungen mit verzögerter freisetzung | |
| CO5200762A1 (es) | Preparacion de piperidin-4-onas sustituidas | |
| ATE266423T1 (de) | Betablocker enthaltende ophtalmische zusammensetzungen | |
| BR9916254B1 (pt) | processo para a preparação de alquileno glicóis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |